ES2346178T3 - Nuevas composiciones, procedimientos y usos de unión de la albúmina - Google Patents

Nuevas composiciones, procedimientos y usos de unión de la albúmina Download PDF

Info

Publication number
ES2346178T3
ES2346178T3 ES08786222.3T ES08786222T ES2346178T3 ES 2346178 T3 ES2346178 T3 ES 2346178T3 ES 08786222 T ES08786222 T ES 08786222T ES 2346178 T3 ES2346178 T3 ES 2346178T3
Authority
ES
Spain
Prior art keywords
seq
albumin binding
albumin
polypeptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08786222.3T
Other languages
English (en)
Spanish (es)
Other versions
ES2346178T1 (es
Inventor
Lars Abrahmsén
Andreas Jonsson
Jakob Dogan
Per-Åke Nygren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affibody AB
Original Assignee
Affibody AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody AB filed Critical Affibody AB
Publication of ES2346178T1 publication Critical patent/ES2346178T1/es
Application granted granted Critical
Publication of ES2346178T3 publication Critical patent/ES2346178T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES08786222.3T 2007-07-31 2008-07-17 Nuevas composiciones, procedimientos y usos de unión de la albúmina Active ES2346178T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96261807P 2007-07-31 2007-07-31
EP07113533 2007-07-31
US962618P 2007-07-31
EP07113533 2007-07-31
PCT/EP2008/059389 WO2009016043A2 (en) 2007-07-31 2008-07-17 New albumin binding compositions, methods and uses

Publications (2)

Publication Number Publication Date
ES2346178T1 ES2346178T1 (es) 2010-10-13
ES2346178T3 true ES2346178T3 (es) 2015-11-02

Family

ID=40057660

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08786222.3T Active ES2346178T3 (es) 2007-07-31 2008-07-17 Nuevas composiciones, procedimientos y usos de unión de la albúmina

Country Status (11)

Country Link
US (2) US8937153B2 (https=)
EP (2) EP2190863B1 (https=)
JP (1) JP5718638B2 (https=)
CN (2) CN104710518A (https=)
AU (1) AU2008281913B2 (https=)
CA (1) CA2694139C (https=)
DE (1) DE08786222T1 (https=)
DK (1) DK2190863T3 (https=)
ES (1) ES2346178T3 (https=)
HK (1) HK1211040A1 (https=)
WO (1) WO2009016043A2 (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2694139C (en) * 2007-07-31 2018-06-05 Affibody Ab Albumin binding polypeptide compositions
WO2010141329A1 (en) * 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
CN102811782A (zh) * 2010-03-08 2012-12-05 通用电气健康护理生物科学股份公司 免疫球蛋白G Fc区结合多肽
WO2011136361A1 (ja) * 2010-04-30 2011-11-03 株式会社 三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
MX2013000314A (es) * 2010-07-09 2013-01-29 Affibody Ab Polipeptidos.
EP2601216B1 (en) * 2010-08-02 2018-01-03 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2012050923A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
DK2643349T3 (da) 2010-11-26 2019-11-25 Molecular Partners Ag Designede repeat-proteiner, der binder til serumalbumin
CA2836873C (en) * 2011-05-21 2019-10-22 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
JP6006309B2 (ja) * 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
ES2732475T3 (es) * 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
US20150133373A1 (en) * 2012-03-28 2015-05-14 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
US20160009767A9 (en) * 2012-03-28 2016-01-14 Affibody Ab Oral administration
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
MX355041B (es) 2012-05-25 2018-03-28 Janssen Biotech Inc Dominios de union a albumina consenso no naturales.
CN111763247B (zh) * 2012-09-25 2024-09-13 阿菲博迪公司 白蛋白结合多肽
US9745350B2 (en) 2012-10-05 2017-08-29 Affibody Ab HER3 binding polypeptides
PL2912051T3 (pl) * 2012-10-25 2018-08-31 Affibody Ab Sposób rozdzielania białek zawierających domenę wiążącą albuminę
AU2013336646B2 (en) 2012-10-25 2016-07-14 Affibody Ab ABD binding polypeptide
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US9255262B2 (en) 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
HK1213194A1 (zh) 2013-03-14 2016-06-30 Daiichi Sankyo Co., Ltd. 用於新型的结合蛋白质pcsk9
CN105247118A (zh) * 2013-03-14 2016-01-13 多伦多大学管理委员会 支架化肽文库以及其制备和筛选方法
ES2660912T3 (es) 2013-03-15 2018-03-26 Affibody Ab Nuevos polipéptidos
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
CN105658228B (zh) 2013-08-28 2020-02-07 瑞典孤儿比奥维特鲁姆有限公司 结合人类补体c5的稳定多肽
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
EP3068425B1 (en) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015091957A1 (en) 2013-12-20 2015-06-25 Affibody Ab Engineered albumin binding polypeptide
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
MX370115B (es) 2014-07-30 2019-12-02 Ngm Biopharmaceuticals Inc Dímeros que comprenden dos polipéptidos, útiles en el tratamiento de trastornos metabólicos.
SI3193930T1 (sl) 2014-09-17 2019-10-30 Affibody Ab Novi polipeptidi
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
PL3212226T3 (pl) 2014-10-31 2020-11-02 Ngm Biopharmaceuticals, Inc. Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
CN108064235A (zh) 2015-01-12 2018-05-22 阿菲博迪公司 Il-17a结合多肽
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2016179568A1 (en) 2015-05-06 2016-11-10 Protomer Technologies, Inc. Glucose responsive insulins
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
JP6882782B2 (ja) 2015-08-04 2021-06-02 デューク ユニバーシティ 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CN107022031A (zh) * 2016-01-29 2017-08-08 中国人民解放军军事医学科学院微生物流行病研究所 融合蛋白HSA1-Vβ1及其应用
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
EP3515928B1 (en) 2016-09-23 2026-01-28 Duke University Unstructured non-repetitive polypeptides having lcst behavior
CN107952080A (zh) * 2016-10-14 2018-04-24 中国科学院过程工程研究所 一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
US11077199B2 (en) 2017-08-09 2021-08-03 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
US20200239575A1 (en) * 2017-10-06 2020-07-30 University Of Utah Research Foundation A fusion protein for targeted therapy of autoimmune disease
EP3691693A4 (en) 2017-10-06 2021-08-25 University Of Utah Research Foundation FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE
US12296018B2 (en) * 2018-01-26 2025-05-13 Duke University Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
EP3765496A1 (en) 2018-03-13 2021-01-20 Affibody AB Polypeptides based on a novel scaffold
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DOUBLE AGONIST FUSION PROTEINS
WO2020051541A1 (en) * 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
US12441772B2 (en) 2019-06-04 2025-10-14 Molecular Partners Ag Designed ankyrin repeat domain with improved stability
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
AU2020342349A1 (en) 2019-09-02 2022-03-03 Biotest Ag Factor VIII protein with increased half-life
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
US20220389066A1 (en) 2019-11-05 2022-12-08 Affibody Ab Polypeptides
WO2021165226A1 (en) 2020-02-17 2021-08-26 Biotest Ag Subcutaneous administration of factor viii
EP3878515A1 (en) * 2020-03-09 2021-09-15 Hober Biotech AB Therapeutic agent targeting her2
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
JP2023554258A (ja) 2020-12-21 2023-12-27 アフィボディ アクティエボラーグ 新規のポリペプチド
JP2024506070A (ja) 2021-02-15 2024-02-08 アフィボディ アクティエボラーグ 新規ｈｅｒ２結合ポリペプチド
EP4476247A1 (en) 2022-02-08 2024-12-18 Affibody AB Protein z variants binding thymic stromal lymphopoietin and their medical use
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
TW202416938A (zh) 2022-08-10 2024-05-01 日商興和股份有限公司 親和體微胞(affibody micelle)藥物複合體
JP2026506075A (ja) 2023-02-17 2026-02-20 アブリンクス エン．ヴェー． 新生児型ｆｃ受容体に結合するポリペプチド
WO2024227930A1 (en) 2023-05-04 2024-11-07 Affibody Ab New polypeptide
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
WO2025158010A1 (en) 2024-01-25 2025-07-31 Affibody Ab Her2-binding polypeptide
CN121041473A (zh) * 2024-05-29 2025-12-02 烟台蓝纳成生物技术股份有限公司 一种双功能性融合蛋白、放射性核素标记物及其应用
CN118666961B (zh) * 2024-08-23 2024-11-26 通化安睿特生物制药股份有限公司 人白蛋白特异结合多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
DE19742706B4 (de) * 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9823071D0 (en) * 1998-10-21 1998-12-16 Affibody Technology Ab A method
GB9911287D0 (en) * 1999-05-14 1999-07-14 Affibody Technology Sweden Ab Self-assembling protein structures
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
CN1169827C (zh) 2001-08-07 2004-10-06 沈阳三生制药股份有限公司 一种增强多肽在体内稳定性药物的生产方法及其应用
CA2464690A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
JP5634008B2 (ja) 2004-04-06 2014-12-03 アフィボディ・アーベー 新規の使用および方法
WO2006056464A2 (en) * 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
CA2694139C (en) * 2007-07-31 2018-06-05 Affibody Ab Albumin binding polypeptide compositions
EP2496598B1 (en) * 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides

Also Published As

Publication number Publication date
EP2190863B1 (en) 2015-09-02
WO2009016043A2 (en) 2009-02-05
US20100273979A1 (en) 2010-10-28
CA2694139C (en) 2018-06-05
US20150158916A1 (en) 2015-06-11
EP2546261A3 (en) 2013-08-14
CN101765608A (zh) 2010-06-30
CN104710518A (zh) 2015-06-17
HK1211040A1 (en) 2016-05-13
US10118949B2 (en) 2018-11-06
WO2009016043A3 (en) 2009-06-04
EP2190863A2 (en) 2010-06-02
AU2008281913B2 (en) 2013-11-07
JP2010534486A (ja) 2010-11-11
CN101765608B (zh) 2015-03-11
CA2694139A1 (en) 2009-02-05
DE08786222T1 (de) 2010-11-25
EP2546261A2 (en) 2013-01-16
ES2346178T1 (es) 2010-10-13
JP5718638B2 (ja) 2015-05-13
US8937153B2 (en) 2015-01-20
AU2008281913A1 (en) 2009-02-05
DK2190863T3 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
ES2346178T3 (es) Nuevas composiciones, procedimientos y usos de unión de la albúmina
ES2981441T3 (es) Proteínas de repetición diseñadas que se unen a la seroalbúmina
ES2880336T3 (es) Métodos y productos para la síntesis de proteínas de fusión
JP2018183171A (ja) アルブミン結合ポリペプチド
EP2161278B1 (en) Single-chain coiled coil scaffold
NZ718153A (en) Stable polypeptides binding to human complement c5
WO2024084203A1 (en) Single domain antibodies binding to albumin
ES2674983T3 (es) Método para la separación de proteínas que contienen un dominio que se une a albúmina
AU2023357539A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
CN121930365A (zh) 一种双特异性嵌合蛋白及应用
HK40059771A (en) Designed repeat proteins binding to serum albumin
WO2025146491A1 (en) Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
HK40012160B (en) Designed repeat proteins binding to serum albumin
HK1189386A (en) Designed repeat proteins binding to serum albumin
BR122023020080B1 (pt) Polipeptídeos e compostos de ligação a c5 do complemento humano
NZ716426A (en) Binding polypeptides having a mutated scaffold